Eterna Therapeutics Inc (ERNA) Stock Price

2.52 ▲ +0.13 (+5.44%)
Open: 2.26 Vol: 0 Day's range: 2.18 - 2.695 Oct 08, 12:41 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
ERNA Technical Analysis
5 mins 30 mins Hourly Daily Weekly
NEUTRAL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 2.45▲ 2.40▲ 2.39▲ 2.56▼ 3.38▼
MA10 2.35▲ 2.34▲ 2.41▲ 2.90▼ 3.91▼
MA20 2.46▲ 2.59▼ 2.68▼ 3.40▼ 5.14▼
MA50 2.89▼ 3.26▼ 3.43▼ 3.96▼ 13.95▼
MA100 3.52▼ 3.97▼ 4.05▼ 5.56▼ 49.77▼
MA200 3.94▼ 4.33▼ 4.68▼ 9.67▼ 450.60▼
  5 mins 30 mins Hourly Daily Weekly
MACD 0.057▲ 0.049▲ 0.033▲ -0.094▼ 0.652▲
RSI 47.010▼ 42.120▼ 38.579▼ 28.405▼ 31.667▼
STOCH 59.065     37.532     32.316     10.086▼ 11.624▼
WILL %R -33.981     -46.875     -56.962     -80.112▼ -95.227▼
CCI 87.566     28.170     -5.046     -111.337▼ -150.582▼
Latest Filters Detected On ERNA
▼ GAP $ERNA Open Gap Down %5 Set Alert
▼ GAP $ERNA Open Gap Down %3 Set Alert
▼ GAP $ERNA Open Gap Down %2 Set Alert
Eterna Therapeutics Inc News
Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
Tuesday, October 06, 2026 05:55 AM
Preclinical data highlighting ERNA-101’s potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade will be presented October 6, 2026, at MD Anderson Cancer Center ...
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Wednesday, September 30, 2026 05:32 AM
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no ...
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First ...
Tuesday, September 15, 2026 01:42 AM
ERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induced arthritis model, providing meaningful proof-of-concept for Ernexa's engineered synthetic iMSC ...
ERNA historical stock data
date open high low close volume
08/10/26 2.26 2.695 2.18 2.52 157,439
07/10/26 2.25 2.39 2.1501 2.39 662,923
06/10/26 2.75 2.96 2.20 2.235 91,550
05/10/26 3.04 3.058 2.70 2.70 21,552
02/10/26 3.00 3.2798 2.90 2.96 40,810
01/10/26 3.13 3.2361 2.84 2.96 35,741
30/09/26 3.24 3.47 3.16 3.20 42,635
29/09/26 3.7382 3.7382 3.0444 3.16 61,865
28/09/26 3.46 3.4999 3.20 3.47 25,791
25/09/26 3.73 3.848 3.40 3.445 21,417
Quote Details
52wk Low:2.15
52wk High:71.498
Vol:0
Avg Vol(3m):966.1K
1Y Chng:-91.87%
1M Chng:-46.78%
Add to Watch List
More Information
Index US Composite
Market Cap. 3.90M